Evotec SE

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING HAMBURG, GERMANY / ACCESSWIRE / May 30, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price of € 23 m. Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia, Rigenerand is a pioneering company in the field of cGMP manufacturing of cell therapies.

Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand

THE MULTI-TARGET RESEARCH AND DEVELOPMENT PARTNERSHIP WILL FOCUS ON SEVERE SKIN DISEASES, INCLUDING IMMUNE-MEDIATED INFLAMMATORY CONDITIONS SUCH AS ATOPIC DERMATITIS AND NON-MELANOMA SKIN CANCER SUCH AS BASAL CELL CARCINOMA THE COLLABORATION LEVERAGES EVOTEC'S DATA-DRIVEN EVO IR&D PLATFORM FOR INTEGRATED DISCOVERY AND DEVELOPMENT OF FIRST-IN-CLASS THERAPIES AND ALMIRALL'S EXPERTISE IN MEDICAL DERMATOLOGY HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / May 19, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) and Almirall S.A. (ALM), a global biopharmaceutical company focused on skin health, announced today a multi-target alliance in Medical Dermatology.

Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology

PARTNERSHIP LEVERAGES IPSC-BASED BETA CELLS FROM EVOTEC'S QRBETA INITIATIVE COMBINED WITH SERNOVA'S PROPRIETARY IMPLANTABLE CELL POUCH™ DEVICE THE GOAL IS THE DEVELOPMENT AND COMMERCIALISATION OF AN OFF-THE-SHELF BETA CELL REPLACEMENT THERAPY FOR INSULIN-DEPENDENT DIABETES EVOTEC MAKES STRATEGIC € 20 M EQUITY INVESTMENT IN SERNOVA EVOTEC/SERNOVA JOINT CONFERENCE CALL AND WEBCAST AT 8.30 AM EDT MAY 17, 2022 HAMBURG, GERMANY, and LONDON, ON / ACCESSWIRE / May 17, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Sernova Corp. (TSX-V: SVA; OTCQB: SEOVF; FSE: PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics today announced a partnership in the field of diabetes. Both Companies will leverage their respective strengths to develop an implantable iPSC-based beta cell replacement therapy for the treatment of insulin-dependent diabetes, including type 1 and 2.

Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes

HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squibb (BMY) in targeted protein degradation, originally signed in 2018. Aim of the eight-year extension is to develop a broad pipeline of molecular glue degraders which are small, drug-like compounds.

Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership

Bristol-Myers

8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING HIGH-PERFORMANCE MULTI-OMICS AND INTEGRATED AI/ML-SUPPORTED DATA ANALYTICS $ 200 M UPFRONT AS WELL AS NEAR-TERM PERFORMANCE-BASED PAYMENTS DEAL POTENTIAL OF $ 5 BN HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders.

Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation

HAMBURG, GERMANY / ACCESSWIRE / May 4, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.

Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022

Evotec SE (EVO) CEO Werner Lanthaler on Q4 2021 Results - Earnings Call Transcript

STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES SUBSTANTIALLY STRENGTHENED BALANCE SHEET PROVIDING VERY GOOD FOUNDATION AND LEVERAGE FOR SUSTAINABLE, LONG-TERM GROWTH POSITIVE OUTLOOK INTO FISCAL YEAR 2022 HAMBURG, GERMANY / ACCESSWIRE / April 12, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today reported financial results and corporate updates for the fiscal year ended 31 December 2021. FINANCIALS REFLECT GREAT PERFORMANCE Group revenues significantly exceeded the revenue target, up 23% to € 618.0 m (+27% like for like, excluding portfolio and fx effects (2020: € 500.9 m)) Base business up 18% (20% adjusted for Sanofi payment in Q1 2020) Adjusted Group EBITDA in line with guidance at € 107.3 m, up 1% (2020: € 106.7 m); like-for-like growth up 18% Unpartnered R&D expenses of € 58.1 m (2020: € 46.4 m up 25%) Very strong liquidity position with € 858.2 m in cash GREAT PROGRESS ACROSS ALL "BUILDING BLOCKS" OF ACTION PLAN 2025 Multiple new and extended integrated drug discovery, development, and manufacturing alliances Important clinical trial initiations and significant progress in co-owned pipeline Excellent progress in iPSC and protein degradation collaborations with Bristol Myers Squibb; Opt-in for EVT8683 and start of clinical development New EVT Innovate partnerships e.g.

Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures

THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A STRATEGIC PARTNERSHIP WITH SECARNA PHARMACEUTICALS HAMBURG, GERMANY / ACCESSWIRE / April 8, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, NASDAQ: EVO) announced today that the Company has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb (BMY) triggering a payment of US$ 16 m to Evotec. The programme further adds to a fast-growing pipeline in neurodegeneration that also includes EVT8683, which entered clinical development end of 2021.

Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb

HAMBURG, GERMANY / ACCESSWIRE / April 5, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809); (NASDAQ:EVO) will announce its financial results for 2021 on Tuesday, 12 April 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.

Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022

FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR DIABETIC NEUROPATHIC PAIN HAMBURG, GERMANY / ACCESSWIRE / March 21, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company received a € 3 m milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into Phase II clinical development as a potential treatment for diabetic neuropathic pain ("DNP"). DNP is a common chronic condition associated with nerve damage caused by high blood sugar levels in diabetic patients.

Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme

LAUNCH OF E.MPD, THE LEADING GLOBAL MOLECULAR PATIENT DATABASE ROLL-OUT AND ACCELERATION OF AI/ML PRECISION TECHNOLOGIES TO INCREASE PROBABILITY OF SUCCESS ("POS") IN RESEARCH, DEVELOPMENT, AND MANUFACTURING EXPANSION OF MANAGEMENT BOARD WITH NEW CHIEF BUSINESS OFFICER (CBO) DR MATTHIAS EVERS AS EXPERT IN AI/ML DRIVEN PROCESSES HAMBURG, GERMANY / ACCESSWIRE / March 2, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, NASDAQ: EVO) today presents at its virtual Capital Markets Day how artificial intelligence ("AI") and machine learning ("ML") enabled precision technologies in discovery and development processes are driving up Probability of Success ("PoS"), i.e. an increasing rate of approvals in the long-run.

Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day

EVOTEC RECEIVES ACCESS TO AN INTERNATIONAL COHORT OF NEPHROTIC SYNDROME PATIENTS COORDINATED BY THE UNIVERSITY OF BRISTOL THE COHORT PROVIDES LONGITUDINAL ACCESS NOT ONLY TO CLINICAL DATA BUT IN PARTICULAR ALSO TO BIOSPECIMENS EVOTEC WILL LEVERAGE ITS MULTI-OMICS ANALYSIS PLATFORM EVO PANOMICS AND THE DATA ANALYTICS PLATFORM EVO PANHUNTER TO IDENTIFY KEY MECHANISMS OF DISEASE AND DIAGNOSTIC MARKERS HAMBURG, GERMANY / ACCESSWIRE / March 1, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has entered into a collaboration with the University of Bristol ("UoB") to expand the Company's molecular patient database in the field of kidney diseases with a focus on nephrotic syndrome. The nephrotic syndrome is a group of symptoms like proteinuria and oedema that indicate kidneys are not working properly.

Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of Bristol

SAN RAFAEL, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--IMIDomics, Inc., a privately held global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs), announced today that Evotec SE (FSE: EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has made an equity investment in the company. In conjunction with the investment, an Evotec representative will join the IMIDomics board of

IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE

Bayer AG BAYRY has discontinued the development of eliapixant and will hand back full rights to the drug to Evotec SE EVO. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Are Evotec Shares Trading Lower On Friday?

HAMBURG, GERMANY / ACCESSWIRE / February 4, 2022 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance. Following a review of the available data, Bayer concluded that the overall benefit no longer outweighs the risk in the actively pursued indications.

Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets

PARTNERSHIP LEVERAGES EVOTEC'S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS HAMBURG, GERMANY / ACCESSWIRE / January 25, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell ("iPSC")-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions.

Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology

COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS LILLY HAS THE RIGHT TO SELECT UP TO FIVE PROGRAMMES HAMBURG, GERMANY / ACCESSWIRE / January 18, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company ("Lilly") in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec's extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention.

Evotec and Lilly Enter into Drug Discovery Collaboration in Metabolic Diseases

EXPANSION LEVERAGES A PROPRIETARY EVOTEC PLATFORM IN THE FIELD OF TARGETED PROTEIN DEGRADATION TO TACKLE SELECTED TARGETS WITH RELEVANCE FOR A RANGE OF NEURODEGENERATIVE CONDITIONS EVOTEC RECEIVES PAYMENTS OF IN TOTAL US$ 15 M FROM BRISTOL MYERS SQUIBB HAMBURG, GERMANY / ACCESSWIRE / January 11, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb (NYSE:BMY) with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer's through a novel approach to targeted protein degradation. Evotec receives payments totalling US$ 15 m from Bristol Myers Squibb.

Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach

EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 EVOTEC IS DEVELOPING A HIGHLY POTENT IMMUNOMODULATORY MOLECULE THAT HOLDS THE POTENTIAL TO AMPLIFY THE IMMUNE RESPONSE AND REDUCE THE RISK OF DIFFICULT DISEASE PROGRESSION AND HOSPITALISATION HAMBURG, GERMANY / ACCESSWIRE / January 3, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT) MDAX/TecDAX, ISIN: DE0005664809 (NASDAQ:EVO) announced today that the Company has been selected by the German Federal Ministry of Education and Research ("BMBF") to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID-19. Evotec is one of three companies receiving a highly competitive grant as part of a new initiative by the BMBF to support the clinical development of novel therapeutic candidates against COVID-19.

Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic

GRANT WILL SUPPORT FULLY INTEGRATED DRUG DISCOVERY PROGRAMME FROM SCREENING TO PRE-CLINICAL DEVELOPMENT CANDIDATE PROJECT LEVERAGES EVOTEC'S WOMEN'S HEALTH PLATFORM AND AI/ML MOLECULAR DESIGN TOOLS HAMBURG, GERMANY / ACCESSWIRE / December 16, 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company has received a US$ 18 m grant from the Bill & Melinda Gates Foundation (Seattle, WA, USA, "the foundation") for the integrated discovery and development of a novel, first-in-class programme to accelerate progress in the area of women's health and contraceptive technology, leveraging Evotec's integrated R&D platform. The project makes use of Evotec's fully-integrated drug discovery and development platforms as well as therapeutic area expertise to take an idea from concept to nomination of a pre-clinical development candidate.

Evotec Receives US$ 18 M Grant for Women's Health

CAMBRIDGE, Mass. & HAMBURG, Germany--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), a leading life science company, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx's pipeline expansion efforts

EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND ACCESSIBLE MEDICINES TO PATIENTS HAMBURG, GERMANY, and CAMBRIDGE, MA / ACCESSWIRE / November 18, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas.

Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership

Evotec SE (EVOTF) CEO Werner Lanthaler on Q3 2021 Results - Earnings Call Transcript

STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH CO-OWNED PIPELINE GAINING MOMENTUM J.POD (R) REDMOND (US) OPERATIONAL SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END) GUIDANCE FOR FULL-YEAR 2021 CONFIRMED WEBCAST AND CONFERENCE CALL TODAY AT 02.00 PM CET HAMBURG, GERMANY / ACCESSWIRE / November 11, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2021. HIGHLIGHTS STRONG REVENUES GROWTH IN ALL BUSINESS AREAS FUELS ONGOING EXPANSION AND STRENGTHENS POSITIVE DEVELOPMENT Group revenues increased by 20% to € 431.0 m (9M 2020: € 360.4 m); like-for-like base revenue growth (excluding portfolio and fx effects) up 26% Milestone revenues of € 27.9 m well above last year (9M 2020: € 8.4 m) Just - Evotec Biologics contributed € 34.7 m to revenues; 43% above last year's level of € 24.3 m Strong progress in both segments: Total EVT Execute revenues up 17% to € 429.8 m (9M 2020: € 367.5 m); EVT Innovate revenues up 35% to € 101.9 m (9M 2020: € 75.7 m) Adjusted Group EBITDA of € 70.1 m (9M 2020: € 76.9 m) primarily driven by higher costs of sales ahead of production start of J.POD (R) Redmond (US), a deliberate increase in unpartnered R&D (up 28%), the overall growth of Evotec and effects from the US public offering; like-for-like growth (excluding portfolio and fx effects) would have reached 16%.

News for Evotec SE Stock (EVO)